Dasatinib in Treating Patients With Stage IV Pancreatic Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically\* confirmed pancreatic cancer
• * Stage IV disease NOTE: \*If biopsy was performed at an outside facility, the histology must be reviewed and confirmed by the Division of Pathology at the City of Hope
• PATIENT CHARACTERISTICS:
• Karnofsky performance status 60-100%
• Life expectancy ≥ 3 months
• Platelet count ≥ 100,000/μL
• Absolute neutrophil count ≥ 1,500/μL
• Bilirubin ≤ 1.5 mg/dL
• ALT and AST ≤ 2.5 times upper limit of normal (ULN)
• Creatinine ≤ 1.5 mg/dL and/or creatinine clearance \> 60 mL/min
• PT and PTT ≤ 1.5 times ULN
• Able to swallow dasatinib whole
• No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix, uterus, or bladder
• No concurrent medical condition which may increase the risk of toxicity, including any of the following:
• * Pleural or pericardial effusion of any grade
• * Clinically significant coagulation or platelet function disorder (e.g., known von Willebrand's disease)
• None of the following cardiac conditions:
• * Uncontrolled angina, congestive heart failure, or myocardial infarction within the past 6 months
• * Prolonged QTc interval (i.e., QTc \> 450 msec) on electrocardiogram
• * History of clinically significant ventricular arrhythmias (i.e., ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
• No hypokalemia or hypomagnesemia that cannot be corrected
• No severe infection requiring treatment
• Completely recovered from other concurrent illnesses, as deemed by the investigator
• Not pregnant
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Recovered from prior major surgery
• No prior irradiation to the planned field
• No prior chemotherapy for pancreatic cancer
• At least 7 days since prior and no concurrent medications that may prolong the QT interval, including any of the following:
• * Quinidine
• * Procainamide
• * Disopyramide
• * Amiodarone
• * Sotalol
• * Ibutilide
• * Dofetilide
• * Erythromycin
• * Clarithromycin
• * Chlorpromazine
• * Haloperidol
• * Mesoridazine
• * Thioridazine
• * Pimozide
• * Cisapride
• * Bepridil
• * Droperidol
• * Methadone
• * Arsenic
• * Chloroquine
• * Domperidone
• * Halofantrine
• * Levomethadyl
• * Pentamidine
• * Sparfloxacin
• * Lidoflazine
• At least 7 days since prior and no concurrent potent CYP3A4 inhibitors
• At least 7 days since prior and no concurrent medications that directly and durably inhibit platelet function, including any of the following:
• * Aspirin or aspirin-containing combinations
• * Clopidogrel
• * Dipyridamole
• * Tirofiban
• * Dipyridamole
• * Epoprostenol
• * Eptifibatide
• * Cilostazol
• * Abciximab
• * Ticlopidine
• * Cilostazol
• No concurrent anticoagulants, including warfarin or heparin/low molecular weight heparin (e.g., danaparoid, dalteparin, tinzaparin, or enoxaparin)
• * Low-dose warfarin for prophylaxis to prevent catheter thrombosis or heparin for flushes of IV lines allowed
• No concurrent IV bisphosphonates during the first 8 weeks of dasatinib therapy
• No concurrent Hypericum perforatum (St. Johns wort)